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Venous thromboembolism (VTE), comprising both deep-vein 
thrombosis (DVT) and pulmonary embolism (PE), is a complication in 
up to 6.7% and 4.3% of high-risk medical admissions, respectively. [1,2] 
PE has been described as the most common preventable cause of 
in-hospital mortality in the USA, killing up to 300 000 patients per 
annum (1 - 8% of those who develop it).[3-5] Survivors experience 
significant morbidity in the form of post-phlebitic syndrome (40%) 
and chronic thromboembolic pulmonary hypertension (4%). Appro-
priate thromboprophylaxis reduces the risk of VTE occurrence by 
45 - 63%, so its importance cannot be overemphasised.[6-8]
Hypercoagulability, venous stasis and vessel wall (endothelial) 
damage encompass the well-known triad of risk factors for VTE.[9,10] 
HIV and tuberculosis (TB) are important overlooked risk factors in 
the South African (SA) setting; however, their impact is not known. 
For various reasons, low-molecular-weight heparin (LMWH) has 
largely replaced unfractionated heparin for pharmacological VTE 
prophylaxis.[11,12] It has proved to be safe[1,13-15] and cost-effective and 
has been widely advocated[16-20] – a strategy that may also prove to 
have the unwanted consequence of overuse in low-risk patients.[21,22]
In an effort to promote the safe and appropriate use of anti-
coagulants in VTE prophylaxis, both SA and the American College 
of Chest Physicians (ACCP) have published guidelines aimed at 
assisting clinicians in decision-making. These guidelines are based 
on VTE risk stratification and considering the individual bleeding 
risk. The ACCP published its latest guideline in 2012,[1] promoting 
the use of the Padua Prediction Score (PPS) that stratifies VTE 
risk[2] and the International Medical Prevention Registry on Venous 
Thromboembolism (IMPROVE) bleeding risk assessment tool.[15] 
No risk assessment models (RAMs) are promoted in the 2013 SA 
published guideline.[23]
Objectives
Some previously published non-SA studies recently showed an 
overall increase in adherence and improvement in the use of 
pharmacological prophylaxis for high-risk patients.[21,22,24] Our aim 
was to describe the use of LMWH at an SA tertiary institution 
based on adherence to local and ACCP guidelines. To achieve this, 
the primary study objectives were to evaluate: (i) the patients’ VTE 
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Background. Venous thromboembolism (VTE) complicates a significant proportion of medical admissions. As well as increasing patient 
morbidity, pulmonary embolism is one of the commonest preventable causes of in-hospital death. An increase in the use of pharmacological 
preventive measures has been advocated in recent years. South African (SA) and international guidelines have been published in an effort 
to promote the safe use of VTE prophylaxis.
Objectives. To describe adherence to both local and international recommendations for VTE prophylaxis in an SA hospital with regard 
to appropriateness of the decision to prescribe or withhold low-molecular-weight heparin (LMWH), and to observe the practice of dose 
adjustment in special population groups.
Methods. This was a prospective, observational study, and data were collected from consenting adults admitted to the medical wards. We 
assessed the patients’ VTE risk, bleeding risk and the presence of contraindications at the time of LMWH prescription as well as the dose 
prescribed, specifically taking into consideration adjustment for renal dysfunction and obesity.
Results. Three hundred and fifty-two patients were enrolled, of whom 51.4% were male and 58.5% received LMWH. Primary outcomes. 
The appropriate overall decision according to both SA and international guidelines was made in 254 cases (72.2%). The inappropriate 
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in 18 cases (5.1%), while 1 case (0.3%) was not categorised. Contraindications to VTE prophylaxis were present in 35 patients (9.9%), but 
9 of these patients nevertheless received LMWH. An incorrect dose was prescribed in 36 cases (17.5%), the most common reason being an 
inappropriate reduction in the dose in mild renal dysfunction. Secondary outcomes. Other medications that may have increased bleeding 
risk were prescribed in 46 patients who received LMWH (22.3%). Mechanical prophylaxis was indicated in 25 (7.1%) of the total sample; 
however, none received this.
Conclusions. Overall adherence to published guidelines for VTE prophylaxis has improved compared with other published reviews on 
the topic, but documentation of patients’ VTE risk in files is poor. Overuse in low-risk patients may be an unintended consequence of the 
widespread advocacy of LMWH use in hospital, highlighting the importance of adequate VTE risk stratification. Incorrect dosing in special 
population groups is an issue that needs to be addressed, as is non-utilisation of mechanical prophylaxis methods.
S Afr Med J 2020;110(3):235-242. https://doi.org/10.7196/SAMJ.2020.v110i3.14279
236       March 2020, Vol. 110, No. 3
RESEARCH
risk factors, quantifying them according to the PPS and the local 
guideline; (ii) bleeding risk according to the IMPROVE bleeding risk 
tool; (iii) the presence of contraindications at the time of prescription, 
i.e. to comment on prescription appropriateness; and (iv) whether 
correct dosing adjustments were made in special populations, 
specifically patients with severe renal failure and obesity. Secondary 
objectives were: (i) to determine whether patients received other 
drugs at the time of LMWH prescription that could increase bleeding 
risk; and (ii) to assess whether mechanical preventive measures 
(including graduated compression stockings (GCS) and intermittent 
pneumatic compression (IPC) devices) were employed.
Methods
Study design and setting
This was a prospective, observational study at Chris Hani Baragwanath 
Academic Hospital, Johannesburg, SA, a large academic facility 
affiliated to the University of the Witwatersrand.
Data collection and sample selection
Data collection took place over July and August 2018 until 352 
patients were enrolled. This was done in the adult medical wards by 
the principal investigator (JAdP). Data were collected from sequential 
patients in one ward until all the qualifying patients were enrolled 
before moving on to the next ward, alternating male and female wards. 
After informed consent had been obtained, all the relevant information 
needed to complete the RAMs (PPS and IMPROVE) and to meet 
the other objectives was extracted from patient files and prescription 
charts. Patients were only seen once at the initial interaction.
Inclusion criteria were all adult patients aged ≥18 years admitted 
to the medical wards. Exclusion criteria were patients aged <18 years, 
those receiving therapeutic anticoagulation, outlying non-medical 
patients, and those who did not sign informed consent.
Guidelines, RAMs and special population assessment
The 2012 ACCP guideline[1] and the 2013 SA guideline and 
recommendations[23] were independently utilised to assess adherence. 
The ACCP guideline recommends the use of the PPS (Table 1) to 
quantify VTE risk and the IMPROVE bleeding risk tool (Table 2) 
to identify patients at high risk of bleeding, while excluding other 
contraindications. According to the PPS used by the ACCP, a score of 
≥4 denotes a high VTE risk, and if bleeding risk is low (IMPROVE 
score <7) and no contraindications are present, pharmacological 
VTE prophylaxis is indicated. If the PPS is ≥4 but bleeding risk is 
high (IMPROVE ≥7) or a contraindication is present, mechanical 
prophylaxis is indicated until bleeding risk or VTE risk resolves. 
VTE prophylaxis is not indicated if the PPS is <4, as these patients 
are at a low risk of VTE.[2,15] The SA guideline recommends that 
all medically ill, bedridden patients (confined to bed or chair, or 
only walking to the bathroom and back) with at least one risk 
factor associated with a high risk of VTE should be given LMWH 
prophylaxis if no contraindication is present and bleeding risk is 
low. Alternatively, all medically ill, bedridden patients with other 
medical conditions, such as acute infections or acute rheumatic 
disease, with at least one additional associated risk factor, qualify for 
VTE prophylaxis. [23] The patients were allocated into eight different 
categories of appropriateness of prescription or omission, based on 
the guidelines. The SA guideline does not provide an objective way 
to quantify bleeding risk, so the IMPROVE score was applied for the 
purpose of this study.
To determine whether appropriate dosage adjustments were 
correctly made in special populations, patient files were checked for 
weight and height to determine whether the body mass index (BMI) 
had been calculated (kg/m2). If had not been calculated, patients 
were weighed and their height checked to determine the BMI. If the 
BMI is ≥35 kg/m2, dosage adjustment to 0.5 mg/kg of enoxaparin 
daily is recommended, with or without the addition of anti-factor Xa 
monitoring, rather than the standard 40 mg enoxaparin daily. [1,11,23,25,26] 
However, specific dosing for VTE prophylaxis in obese patients 
is controversial and no specific dosage is recommended in either 
the local or the ACCP guideline owing to lack of evidence.[11,25,26] 
In the present study, if the BMI was ≥35 kg/m2 the correct dose of 
enoxaparin was presumed to be 0.5 mg/kg/d, rounded to the nearest 
commercially available pre-filled syringe formulation.
Renal function was assessed by reviewing the estimated glomerular 
filtration rate (eGFR) provided by the National Health Laboratory 
Service (NHLS) laboratory on all creatinine samples submitted to it. 
The reported eGFR was used instead of creatinine clearance (CrCl) 
for dose adjustment assessment, even though most of the sourced 
references refer to CrCl. This is an acceptable approach, supported 
by some evidence.[27] A dose adjustment to 20 - 30 mg enoxaparin 
daily is recommended if the CrCl is ≤30 mL/min according to the 
latest international recommendations, the South African Medicines 
Formulary and the local drug package insert.[11,12,14] Adjustment for 
renal dysfunction, although mentioned, is not specifically addressed 
in the SA VTE guideline.[23] Forty milligrams of enoxaparin given 
subcutaneously daily is regarded as the appropriate dose in patients 
with an eGFR >30 mL/min and a BMI <35 kg/m2.[1,14]
Table 1. Padua Prediction Score[2]
Active cancer 3
Previous VTE 3
Reduced mobility 3
Known thrombophilic condition 3
Recent (≤1 month) trauma/surgery 2
Age ≥70 years 1
Cardiac or respiratory failure 1
Acute myocardial infarction or ischaemic stroke 1
Acute infection or rheumatological disorder 1
BMI ≥30 kg/m2 1
Ongoing hormonal treatment 1
VTE = venous thromboembolism.
Table 2. IMPROVE bleeding risk assessment tool[15]
Moderate renal failure (CrCl 30 - 50 mL/min) 1
Male sex 1
Age 40 - 84 years 1.5
Active cancer (past 6 months) 2
Rheumatic disease 2
Central venous catheter 2
Admission to intensive care 2.5
Severe renal failure (CrCl <30 mL/min) 2.5
Liver insufficiency (INR >1.5) 2.5
Age ≥85 years 3.5
Thrombocytopenia (<50 × 109/L) 4
Recent (3 months) bleeding 4
Active gastrointestinal ulcer 4.5
IMPROVE = International Medical Prevention Registry on Venous Thromboembolism; 
CrCl = creatinine clearance; INR = international normalised ratio.
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Statistical analysis
Categorical variables including risk factors and dosing were des-
cribed using proportions, horizontal bar graphs and pie charts. 
Continuous variables (such as age, weight, height, BMI, PPS) were 
described using means and standard deviations (SDs). Student’s t-test 
for comparison of means was used to compare gender differences 
in age, weight, height, BMI and PPS. Pearson’s χ2 test was used to 
explore associations between categorical variables including SA and 
international guidelines as well as IMPROVE scores and LMWH 
prescriptions. Pearson’s correlation coefficient was used to explore 
associations between age and weight. All analysis was done using 
Excel 2013 (Microsoft, USA) and Stata 15 (StataCorp, USA).
Results
Patient characteristics
After a total of 596 files were assessed, 352 patients were enrolled 
(51.4% males). Of the 244 excluded, 8 refused consent. In 132 
patients, consent was not obtainable owing to a reduced level of 
consciousness, confusion or inability to understand the consent 
process. Fourteen patients were <18 years of age and 90 patients were 
receiving therapeutic anticoagulation. No patient withdrew consent 
after consenting, so all 352 cases were analysed. Table 3 summarises 
some of the baseline clinical characteristics. The HIV prevalence was 
39.2%, and 48 patients (13.6%) were receiving TB treatment.
Age was normally distributed, with a mean (SD) of 48.54 (15.35) 
years for admitted medical patients. There were no significant 
differences in mean age between males (48.83 (14.38) years) and 
females (48.22 (16.34) years) (p=0.712). Mean weight was 65.74 
(16.54) kg for male patients and 68.36 (20.26) kg for female patients 
(p=0.230). However, female patients had a significantly higher mean 
BMI than male patients, 26.34 (7.62) kg/m2 v. 22.13 (5.41) kg/m2, 
respectively (p<0.001). There was no correlation between age and 
weight (correlation coefficient R=0.115). Fig. 1 shows the VTE risk 
factors in the study population according to the PPS, while Figs 2 
and 3 summarise the high and other risk factors, respectively, in the 
study population according to the SA guideline. Fig. 4 indicates the 
bleeding risk factors according to the IMPROVE score.
Even though a formal IMPROVE score was not documented in 
any patient file, clinicians were significantly less likely to prescribe 
LMWH for patients with a high risk of bleeding (p=0.013). However, 
6 (31.6%) of the 19 patients with a high risk of bleeding received 
LMWH.
Primary and secondary outcomes
Table 4 summarises the primary outcomes, while Tables 5 and 6 
describe the eight categories of prescription/omission appropriateness 
and global clinician decision, respectively. The secondary outcomes 
are described in Table 7. The mean (SD) PPS was 3.62 (1.90) for males 
and 3.58 (2.01) for females (p=0.848). There was a strong correlation 
between the SA and ACCP VTE prophylaxis guidelines, with a 93.1% 
agreement on LMWH omission and a 94.5% agreement on LMWH 
prescription (p<0.001). Of the patients, 46 were prescribed medications 
that potentially increase bleeding risk when given concomitantly with 
LMWH: these were aspirin (n=38 patients), aspirin and clopidogrel 
(n=4), warfarin (n=1) and non-steroidal anti-inflammatory drugs 
(n=3). There was no significant difference in prescription of these 
medications between patients who were receiving LMWH and those 
who were not (p=0.066, p=0.621, p=0.585 and p=0.669, respectively, 
for the abovementioned medications). A total of 52 contraindications 
to LMWH use were present in 35 patients: IMPROVE score ≥7 (n=19), 
international normalised ratio (INR) >1.5 (n=11), thrombocytopenia 
(n=10), cerebral haemorrhage (n=5), active peptic ulcer disease (n=5), 
malignant hypertension (n=1) and dissecting aortic aneurysm (n=1). 
An INR result was not available in 271 (77.0%) of all patients in 
calculating the IMPROVE score.
A total of 351 of the 352 (99.7%) patients could be allocated to a 
category, while 1 was excluded because crucial information was not 
available.
Three patients had a contraindication present at the time of 
prescription of VTE prophylaxis other than an IMPROVE score of 
≥7: thrombocytopenia (<50  × 109/L) (n=1), coagulopathy with an 
INR >1.5 without oral anticoagulation (n=1), and hypertensive crisis 
(n=1).
Discussion
Evaluating the use of anticoagulants and adherence to guidelines 
are both important to optimise patient care and limit adverse events 
when VTE prophylaxis is considered. To our knowledge, this is the 
first SA study to evaluate the use of LMWH for VTE prophylaxis. 
The study showed 72.4% overall compliance with both a local and 
an international guideline (prescription and omission of LMWH) 
and 77.3% compliance with at least one of these guidelines. Dosing 
was considered separately and was not included in the assessment of 
prescription appropriateness.
Bateman et al.[28] found that improved adherence to VTE prevention 
guidelines resulted in an increased rate of VTE risk documentation, 
rising from 51.5% in 2009 to 71.2% in 2010 (p<0.001), while another 
before-after observational study, published in 2005 by Scaglione et 
al.,[24] showed that adherence to VTE prophylaxis guidelines improved 
Table 3. Baseline clinical characteristics (N=352 unless 
otherwise stated)
Characteristics n (%)
Weight documented in file
Yes 3 (0.9)
No 349 (99.2)
 Unable to weigh during data collection (for 
those in whom weight was not documented)
63 (17.9)
Height documented in file
Yes 3 (0.9)
No 349 (99.2)
 Unable to measure during data collection (for 
those in whom height was not documented)
65 (18.5)
Platelets checked
No 2 (0.6)
Yes 350 (99.4)
Renal function (eGFR, mL/min/1.73 m2)
≤30 42 (12.0)
31 - 59 45 (12.8)
≥60 264 (75.2)
Not available 1 (0.3)
LMWH prescribed
No 146 (41.5)
Yes 206 (58.5)
LMWH doses (mg) (N=206)
20 35 (17.0)
40 169 (82.0)
60 2 (1.0)
eGFR = estimated glomerular filtration rate; LMWH = low-molecular-weight heparin.
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prescription in high-risk medical patients 
from 25% to 41.7%, a significant increase 
(p=0.0075). In our study, 236 patients were 
at high risk of VTE according to the ACCP 
guideline (PPS ≥4), and 173 (73.3%) of 
those patients received LMWH. Of the 231 
patients who were at high risk according 
to the SA guideline, 169 (73.2%) received 
LMWH. The prescription in high-risk 
VTE patients at this institution is markedly 
better than the results of Scaglione et al.;[24] 
however, the National Institute for Health 
and Clinical Excellence (NICE) guidelines 
were employed at their institution.[24]
With regard to the overuse of LMWH 
in low-risk patients, a concern raised in 
a recent review by Flanders et al.,[29] the 
trend towards improving pharmacological 
prophylaxis for VTE has also led to an 
increase in inappropriate prescription in 
low-risk patients. According to this database 
review of 44 775 patients, 57.1% of low-
risk patients received pharmacological 
prophylaxis inappropriately.[29] This figure 
was significantly higher than in a smaller 
cohort study of 80 patients, where 28.8% of 
patients received LMWH inappropriately 
based on the same risk predictive score 
(PPS).[22] Similarly, in our study a total of 
37 (30.6%) of the 121 patients at low risk 
of VTE according to the SA guideline, and 
a total of 33 (28.5%) of those at low risk 
according to the PPS, received LMWH. A 
total of 28/108 (25.9%) who were at low 
risk of VTE according to both guidelines 
inappropriately received LMWH.
We also looked at the prescription of 
LMWH in patients who had a contra-
indication to administration of the drug. 
AlHajri and Gebran[22] reported a prevalence 
of 13.75% in their cohort, but this was 
proportional to the total of 80 of their 
patients who received LMWH (both low- 
and high-risk patients were included). This 
proportion was similar to those described by 
Bateman et al.[28] in 2009 and 2010 (14% and 
15%, respectively). Flanders et al.[29] reported 
in their analysis that 12.3% of high VTE 
risk patients who had a contraindication 
to VTE prophylaxis nevertheless received 
it. In our analysis, 24 patients were at high 
VTE risk (according to both guidelines) and 
also had a contraindication, and 9 (37.5%) 
of these patients were prescribed LMWH. 
Compared with AlHajri and Gebran’s[22] 
and Bateman et al.’s[28] studies, significantly 
fewer (n=9, 4.4%) of the total number of 
patients who received LMWH in the present 
study had a contraindication at the time of 
prescription.
Underuse of LMWH in high-risk patients 
has decreased in recent years as a result 
of widespread advocacy of pharmacological 
prophylaxis.[30] In the review by Flanders 
et al.,[29] 22% of high-risk patients did not 
receive LMWH despite no contraindication 
being present. Similarly, in our study LMWH 
was inappropriately omitted in 42 (18.8%) of 
223 patients who were at high VTE risk 
according to both guidelines.
An INR was not available in 271 (77.0%) 
of all patients, and this could have biased 
the IMPROVE scores. We used multiple 
imputation to impute missing INR results 
and calculated a contrived IMPROVE score. 
There was a 99% agreement on assignment 
to low bleeding risk, and a 100% agreement 
on assignment to high bleeding risk. These 
agreement values confirmed that in our 
study, although the INR was missing in most 
cases, the score calculated even without an 
INR result did not significantly bias our 
results. As most patients had a low-risk 
score, the addition of the extra points for 
a deranged INR did not change the score 
from <7 to ≥7. Since an INR is not clinically 
indicated in most patients, it is unlikely that 
it would be deranged if the clinician felt it 
unnecessary to measure the INR. We cannot 
advocate routine testing for the purposes of 
calculating an IMPROVE score, particularly 
in resource-limited settings.
Appropriate dosing is of the utmost 
importance, and both over- and under-
dosing is inappropriate, with the concerns 
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Fig. 1. VTE risk factors according to the Padua Prediction Score.[2] (VTE = venous thromboembolism; 
MI = myocardial infarction; D/O = disorder.)
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Fig. 2. High VTE risk factors according to the South African guideline.[23] (VTE = venous 
thromboembolism; COPD = chronic obstructive pulmonary disease; ICU = intensive care unit.)
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being increased risk of bleeding and 
subtherapeutic anti-factor Xa activity, 
respectively. In considering dosages, 
morbidly obese patients and those with 
severe renal dysfunction have generally been 
under-represented in clinical trials. [11,12,25,26] 
The concern in obese patients is that altered 
pharmacokinetics may lead to reduced 
heparin activity.[11,25,26] LMWH is excreted 
renally, and pharmacokinetic studies have 
shown a significantly increased exposure 
to anti-factor Xa activity with a CrCl 
<30 mL/min, indicating the need for a dose 
adjustment.[11,12,14] In the present study, 36 
(17.5%) of patients who received LMWH 
received an incorrect dose. In comparison, 
in two other trials 28.7% and 40% of 
patients, respectively, were reported to have 
received an incorrect dose. [22,31] In 2  cases, 
no comment was made regarding the 
appropriateness of the dose of enoxaparin. In 
both cases, the BMI was >35 kg/m2 (weight 
117 kg and 110 kg, respectively), and the 
GFR was <30 mL/min. One patient received 
20 mg enoxaparin and the other 60 mg. We 
consider that in a setting where numerous 
reasons for altered pharmacokinetics exist, 
anti-factor Xa activity should ideally be 
measured to guide dosing. The reasons for 
inappropriate dosing are shown in Fig. 5.
Documentation of patients’ weight and 
height was poor, with >99% of patients not 
having a documented weight or height in 
the file, in no case with a recorded reason. 
During our assessment, weight and height 
was obtainable in >80% of patients, the 
remainder being too ill to stand upright and 
unassisted on a scale.
ACCP guidelines make a weak recom-
mendation (grade 2C) for the use of 
mechanical methods in patients at high risk 
of VTE and where pharmacological methods 
are contraindicated or the patient has a 
significant bleeding risk.[1] According to these 
criteria, 25 patients in this study qualified 
for mechanical prophylaxis; however, 
none received it. The use of mechanical 
prophylaxis by IPC in a resource-limited 
setting is inherently challenging. Use of 
IPC also further limits patient mobilisation, 
and these devices always need to be in 
working order. The use of GCS, however, is 
an alternative that still needs to be explored 
in our setting.
One of the major drawbacks of 
the IMPROVE score is that it does not 
include the use of other medications that 
may potentially increase bleeding risk.[15] 
Forty- six of our patients had concomi tantly 
prescribed LMWH and other medications, 
although we did not assess the effect this had 
on bleeding events.
Study limitations
The main weakness of this study was that 
no follow-up was done, so we were not 
able to assess clinical outcomes. Also, a key 
population was under-represented: those 
who were too ill to sign consent. Precise 
dosing was difficult, especially in obese 
patients, as pre-filled, fixed-dose syringes 
were the only formulation available. The 
duration of adequate prophylaxis was also 
not assessed in this study. However, the 
study provides useful data, adds valuable 
information to the literature topic, and 
highlights the importance of awareness and 
adherence to available guidelines.
Conclusions
Various factors account for the inappro-
priate use of LMWH for VTE prophylaxis. 
These include lack of adherence to and 
poor implementation of available guidelines/
recommendations, incorrect dosing in 
special population groups, and failure to 
actively exclude contraindications to the 
prescription of LMWH. At our institution 
there was 72.4% compliance with both local 
and ACCP guidelines and 77.3% compliance 
with at least one of the guidelines, a 
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Table 4. Primary outcomes (N=352 unless otherwise stated)
Endpoint n (%)
PPS ≥4 (ACCP guideline indications met) 236 (67.1)
SA VTE guideline indications met 231 (65.6)
Both guidelines indications met 223 (63.4)
IMPROVE bleeding risk score
≥7 (high bleeding risk) 19 (5.4)
<7 (low bleeding risk) 331 (94.0)
Unable to comment 2 (0.6)
Contraindications to LMWH present
No 314 (89.2)
Yes 35 (9.9)
Unable to comment 3 (0.9)
Contraindication/s present in those who were prescribed LMWH (9/206)
IMPROVE ≥7 6 (2.9)
Other contraindication present 3 (1.5)
Total 9 (4.4)
Appropriate dosages in those prescribed LMWH (N=206)
No 36 (17.5)
Yes 170 (82.5)
Doses by eGFR and BMI 20 mg, n (%) 40 mg, n (%) 60 mg, n (%) Total, N
eGFR (mL/min/1.73 m2) (N=206)
≤30 16 (69.6) 6 (26.1) 1 (4.4) 23
31 - 59 7 (21.2) 25 (75.7) 1 (3.0) 33
≥60 12 (8.0) 138 (92.0) 0 150
BMI (kg/m2) (N=164)
<35 25 (16.8) 123 (82.6) 1 (0.7) 149
≥35 1 (6.7) 13 (86.7) 1 (6.7) 15
PPS = Padua Prediction Score; ACCP = American College of Chest Physicians; SA = South African; VTE = venous thromboembolism; IMPROVE = International Medical Prevention Registry  
on Venous Thromboembolism; LMWH = low-molecular-weight heparin; eGFR = estimated glomerular filtration rate; BMI = body mass index.
Table 5. Appropriate prescription or omission of low-molecular-weight heparin by category (N=352)
Category
Prescribed 
(P) or 
omitted (O)
Meets local 
SA guideline 
indications
Meets international 
guideline indications 
(PPS ≥4)
IMPROVE 
score
Contraindications 
to VTE prophylaxis n (%)
1 Appropriately prescribed according 
to local guidelines only
P Yes No <7 None 5 (1.4)
2 Appropriately prescribed according 
to international guidelines only
P No Yes <7 None 9 (2.6)
3 Appropriately prescribed according 
to both guidelines
P Yes Yes <7 None 154 (43.8)
4 Appropriately omitted according to 
local guidelines only
O No Yes <7 None 2 (0.6)
5 Appropriately omitted according to 
international guidelines only
O Yes No <7 None 2 (0.6)
6 Appropriately omitted according to 
both guidelines
O Guideline indications irrelevant as 
contraindication/s identified
IMPROVE ≥7 or 
contraindications present
26 (7.4)
O No No Irrelevant as guideline indications 
not met
74 (21.0)
7 Inappropriately prescribed according 
to both guidelines
P Guideline indications irrelevant as 
contraindication/s identified
IMPROVE ≥7 or 
contraindications present
9 (2.6)
P No No Irrelevant as guideline indications 
not met
28 (8.0)
8 Inappropriately omitted according to 
both guidelines
O Yes Yes <7 None 42 (11.9)
9 Unable to evaluate 1 (0.3)
SA = South African; PPS = Padua Prediction Score; IMPROVE = International Medical Prevention Registry on Venous Thromboembolism; VTE = venous thromboembolism.
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superior outcome compared with other 
studies. Various RAMs are available to assist 
clinicians in decision-making (including the 
PPS and IMPROVE), but this study has 
shown that there is no difference between 
the use of a comprehensive guideline 
that does not use any RAMs (SA VTE 
guideline) and a guideline that advocates 
the PPS (ACCP VTE guideline) in VTE 
risk stratification. The concern regarding 
overuse of VTE prophylaxis in low-risk 
patients was supported by our study, and was 
a greater problem than LMWH underuse in 
high-risk patients. Low-risk patients need 
to be identified more consistently to avoid 
unnecessary risk and cost.
We recommend that, wherever possible, 
patients’ BMI should be determined on 
admission to identify those for whom the 
dose of LMWH requires adjustment. The 
NHLS also provides a readily available 
eGFR whenever renal function is assessed 
by measurement of serum creatinine 
levels. We recommend that this be used 
to avoid incorrect dosing in severe 
renal dysfunction, as well as to ensure 
correct dosing in patients with mild renal 
impairment. The use of GCS is an option 
for mechanical prophylaxis that needs 
further investigation into its feasibility in 
a resource-limited environment. Further 
local studies are needed to assess the impact 
of implementation of our recommendations 
as well as the reduction of adverse outcomes 
due to inappropriate prescription or 
omission of VTE prophylaxis.
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